HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Investment analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Rigel Pharmaceuticals in a research note issued on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of $0.68 per share for the quarter, down from their previous forecast of $1.18. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $3.51 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.81 EPS.

RIGL has been the subject of several other reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Friday, July 17th. Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a report on Thursday. Finally, Zacks Research lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $54.50.

Rigel Pharmaceuticals Stock Performance

Shares of RIGL opened at $39.22 on Friday. The firm has a market cap of $725.57 million, a PE ratio of 2.40 and a beta of 1.16. The firm’s 50 day moving average price is $36.68 and its 200 day moving average price is $32.98. Rigel Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $52.24.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.09 by $0.79. Rigel Pharmaceuticals had a return on equity of 22.95% and a net margin of 116.30%.The business had revenue of $78.70 million during the quarter, compared to analysts’ expectations of $55.27 million.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of institutional investors have recently modified their holdings of RIGL. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Rigel Pharmaceuticals by 400.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock worth $55,000 after buying an additional 1,020 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Rigel Pharmaceuticals in the 3rd quarter worth $62,000. Wexford Capital LP acquired a new position in Rigel Pharmaceuticals during the 3rd quarter worth $66,000. CWM LLC lifted its position in Rigel Pharmaceuticals by 217.0% during the 4th quarter. CWM LLC now owns 1,791 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 1,226 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Rigel Pharmaceuticals by 130.7% during the second quarter. Legal & General Group Plc now owns 4,310 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 2,442 shares during the period. Institutional investors own 66.23% of the company’s stock.

Insider Buying and Selling at Rigel Pharmaceuticals

In related news, Director Kamil Ali-Jackson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.00, for a total value of $87,500.00. Following the completion of the sale, the director directly owned 10,125 shares in the company, valued at approximately $354,375. The trade was a 19.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.47% of the company’s stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).